Cargando…
Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
INTRODUCTION: The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-asso...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570879/ https://www.ncbi.nlm.nih.gov/pubmed/34745267 http://dx.doi.org/10.1155/2021/9673453 |
_version_ | 1784594909583376384 |
---|---|
author | Tunjungputri, Rahajeng N. Tetrasiwi, Erpryta Nurdia Veronica, Merlinda Pandelaki, Jacub Ibrahim, Fera Nelwan, Erni Juwita |
author_facet | Tunjungputri, Rahajeng N. Tetrasiwi, Erpryta Nurdia Veronica, Merlinda Pandelaki, Jacub Ibrahim, Fera Nelwan, Erni Juwita |
author_sort | Tunjungputri, Rahajeng N. |
collection | PubMed |
description | INTRODUCTION: The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake. CONCLUSION: We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination. |
format | Online Article Text |
id | pubmed-8570879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-85708792021-11-06 Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 Tunjungputri, Rahajeng N. Tetrasiwi, Erpryta Nurdia Veronica, Merlinda Pandelaki, Jacub Ibrahim, Fera Nelwan, Erni Juwita Case Rep Med Case Report INTRODUCTION: The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake. CONCLUSION: We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination. Hindawi 2021-10-29 /pmc/articles/PMC8570879/ /pubmed/34745267 http://dx.doi.org/10.1155/2021/9673453 Text en Copyright © 2021 Rahajeng N. Tunjungputri et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Tunjungputri, Rahajeng N. Tetrasiwi, Erpryta Nurdia Veronica, Merlinda Pandelaki, Jacub Ibrahim, Fera Nelwan, Erni Juwita Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
title | Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
title_full | Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
title_fullStr | Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
title_full_unstemmed | Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
title_short | Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
title_sort | vaccine-associated disease enhancement (vade): considerations in postvaccination covid-19 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570879/ https://www.ncbi.nlm.nih.gov/pubmed/34745267 http://dx.doi.org/10.1155/2021/9673453 |
work_keys_str_mv | AT tunjungputrirahajengn vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19 AT tetrasiwierprytanurdia vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19 AT veronicamerlinda vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19 AT pandelakijacub vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19 AT ibrahimfera vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19 AT nelwanernijuwita vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19 |